Lv3
324 积分 2024-04-28 加入
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy
11天前
已完结
Immune reconstitution after CD7 CAR ‐T cell therapy for refractory/relapsed acute T‐lymphoblastic leukaemia/lymphoblastic lymphoma (R/R T‐ ALL / LBL )
12天前
已完结
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial
18天前
已完结
Expert Consensus on Cytomegalovirus Management in Recipients of CAR-T Cell and Bispecific Antibody Therapies
1个月前
已完结
Systemic capillary leak syndrome
3个月前
已完结
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy
3个月前
已完结
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
3个月前
已完结
The mechanisms and countermeasures for CAR-T cell expansion and persistence deficiency
3个月前
已完结
A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
3个月前
已完结
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
4个月前
已完结
皖公网安备34019202002308
